Browse

Interleukin-18 promoter polymorphisms in patients with Behcet's disease

Cited 29 time in Web of Science Cited 32 time in Scopus
Authors
Lee, Yun Jong; Kang, Seong Wook; Park, Jeong Jin; Bae, Young Deok; Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook
Issue Date
2006-10-24
Publisher
Elsevier
Citation
Hum Immunol. 2006 Oct;67(10):812-8. Epub 2006 Aug 23.
Keywords
AdolescentAgedArthritis/etiologyBehcet Syndrome/complications/*genetics/immunologyFemaleGene FrequencyGenotypeHaplotypesHeterozygoteHomozygoteHumansInterleukin-18/*genetics/immunologyKoreaMalePolymorphism, Single Nucleotide/*geneticsPromoter Regions, Genetic/*geneticsUveitis/etiology
Abstract
Behcet's disease (BD) is an idiopathic systemic inflammatory disease and is considered to be a T helper 1 (Th1) type cytokine driven disorder. Moreover, levels of interleukin-18 (IL-18), a pivotal mediator of Th1 cytokine response, have been reported to be upregulated in BD. Therefore, we investigated the distribution of IL-18 promoter -607 C/A and -137 G/C polymorphisms in 103 BD patients (mean age 41.0 years; 48 male, 55 female) using allele-specific-polymerase chain reaction. As compared with healthy control subjects, BD patients had a significantly higher frequency of the -607 CC genotype (42.7% vs 23.3%, odds ratio [OR] = 2.455, 95% confidence interval [CI] = 1.350-4.461, p(c) = 0.021) and a higher frequency of the -607 C allele (60.7% vs 48.1%, OR = 1.668, 95% CI = 1.129-2.464, p = 0.0101). Haplotype analysis showed that BD patients had significantly less -607A/-137G haplotype (27.3% vs 44.2%, OR = 0.469, 95% CI = 0.268-0.820, p(c) = 0.032) and -607A/-137G haplotype homozygote (5.8% vs 20.4%, OR = 0.242, 95% CI = 0.096-0.612, p(c) = 0.014) than control subjects. In addition, the frequency of -607C/-137G haplotype homozygote was significantly higher in BD patients than control subjects (48.5% vs 20.4%, OR = 3.684, 95% CI = 1.997-6.791, p(c) = 0.0014). Although there were no associations between the polymorphisms and clinical manifestations or severity, patients with the -607 CC genotype or -607C/-137G haplotype homozygote showed significantly earlier symptom development (p = 0.034 by ANOVA; p = 0.009 by t-test, respectively) than those with other genotypes or diplotypes. These results suggest that the IL-18 promoter gene is a candidate susceptibility gene in BD patients.
ISSN
0198-8859 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17055358

https://hdl.handle.net/10371/27800
DOI
https://doi.org/10.1016/j.humimm.2006.07.012
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse